AstraZeneca Cut to Hold From Buy by Intron Health
AstraZeneca Target Cut to GBP120 From GBP140 by Intron Health
BenevolentAI to Present on Explainable AI for Drug Discovery at BioTechX Europe 2024
cspc pharma's early trading rose by more than 6%, the group signed an exclusive licensing agreement with astrazeneca.
CSPC Pharma (01093) rose 5.51% in the morning session, now at 7.09 Hong Kong dollars, with a turnover of 0.585 billion Hong Kong dollars. CSPC Pharma has issued an announcement.
HK stocks unusual movement | cspc pharma (01093) surged more than 6% in the morning, entering into an exclusive authorization agreement with astrazeneca, with a total consideration of 2 billion US dollars.
CSPC Pharma(01093) surged over 6% in early trading, as of press time, up 3.87% to 6.98 Hong Kong dollars, with a turnover of 0.497 billion Hong Kong dollars.
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Astrazeneca (AZN) Loses -5.29% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
Goldman Sachs: Buy rating on cspc pharma, the trade with astrazeneca is an important step in global expansion.
Oct 9, Goldman Sachs released a research report, giving CSPC Pharma a target price of 10.03 Hong Kong dollars based on the sum-of-the-parts valuation method (SOTP), reflecting a 40.9% upside potential, and rated it as a "buy". The report stated that CSPC Pharma announced plans to license YS2302018 (a small molecule inhibitor of lipoprotein(a) [Lp(a)] in preclinical stage) and any products containing YS2302018 globally. This marks the company's first collaboration with astrazeneca, which the bank considers an important step in the company's global expansion. The company aims to complete 1-2 more global deals by 2024.
Goldman Sachs: Initiates a "buy" rating on cspc pharma with a target price of 10.03 Hong Kong dollars.
Goldman Sachs released a research report stating a 'buy' rating for cspc pharma (01093) with a target price of 10.03 Hong Kong dollars. The company aims to complete 1-2 BD trades within 2024, emphasizing the continuous review of product lines and strengthening business expansion efforts. The bank expects more trades to occur in the future. It was noted that cspc pharma announced plans to authorize YS2302018 (a small molecule inhibitor of lipoprotein(a) (Lpa) in the preclinical stage) and any products containing YS2302018 globally. The company's first collaboration with Astrazeneca, according to the bank, is the company's global expansion.
Arcus a New Overweight at Wells Fargo on Potential of Casdatifan in Kidney Cancer
AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
Another old pharmaceutical company successfully transformed through innovation.
Intensive product BD, heavyweight personnel appointments, 5 billion buyback plan, cspc pharma's stock price soared over 60% in 3 weeks.
AstraZeneca's Phase III Trial of Treatment for Asthma Meets Its Primary Endpoint
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95
Express News | Nomura Securities: CSPC Pharma will benefit from its exclusive licensing agreement with Astrazeneca.
CSPC Pharmaceutical Set to Benefit From Exclusive Licensing Agreement With AstraZeneca -- Market Talk
Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)
HK stocks are in a special situation | CSPC Pharma (01093) opened more than 9% higher, reaching an exclusive licensing agreement with astrazeneca for YS2302018.
CSPC Pharma (01093) opened more than 9% higher, up 9.55% as of the time of publication, at 7.8 Hong Kong dollars, with a turnover of 0.114 billion Hong Kong dollars.
Selected Announcements | Cosco Shipping Holdings expects a net profit increase of over 280% in the third quarter; cspc pharma reaches a nearly 2 billion US dollar drug authorization agreement.
greentown china's cumulative contract sales amount in the first 9 months is approximately 187.2 billion yuan, a decrease of 2.65% year-on-year; poly property's cumulative contract sales in the first 9 months is 40.2 billion yuan, a decrease of 12.42% year-on-year; great wall motor's sales volume in the first 9 months is approximately 0.8538 million units, a decrease of 1.18% year-on-year.
Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge